News
- Author:
- Susan London
Publish date: January 21, 2018
SAN FRANCISCO – “It’s becoming clear that right-sided tumors are different from left-sided tumors.”
News
- Author:
- Susan London
Publish date: January 3, 2018
SAN ANTONIO – In an updated joint analysis of TEXT and SOFT, benefit of AI plus OFS over tamoxifen plus OFS was sustained, with a 4.0% absolute gai...
News
- Author:
- Susan London
Publish date: January 3, 2018
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.
News
- Author:
- Susan London
Publish date: January 2, 2018
SAN ANTONIO – CTS5 was validated among 11,446 postmenopausal women treated for ER+ breast cancer who had had 5 years of adjuvant endocrine therapy....
News
- Author:
- Susan London
Publish date: January 2, 2018
SAN ANTONIO – The results of the EndoPredict test appear to predict tumor response in patients with early hormone receptor–positive, HER2-negative ...
News
- Author:
- Susan London
Publish date: December 26, 2017
SAN ANTONIO – The biologic risk signature was not only prognostic, but also predictive for radiotherapy benefit.
News
- Author:
- Susan London
Publish date: December 18, 2017
SAN ANTONIO – Compared with peers who had stable weight, women who lost at least 5% of their body weight had a lower risk of invasive breast cancer...
News
- Author:
- Susan London
Publish date: December 11, 2017
SAN ANTONIO – Pembrolizumab overcomes trastuzumab resistance in some HER2-positive advanced breast cancer if the tumor expresses PD-L1.
News
- Author:
- Susan London
Publish date: December 9, 2017
SAN ANTONIO
News
- Author:
- Susan London
Publish date: December 8, 2017
SAN ANTONIO – Women in the Women’s Health Initiative Observational Study who lost at least 5% of their body weight had a significant 12% reduction ...
News
- Author:
- Susan London
Publish date: December 8, 2017
SAN ANTONIO – Women were less likely to experience recurrence or die of breast cancer if they were given dose-intensified chemotherapy.
Video
- Author:
- Susan London
Publish date: December 7, 2017
SAN ANTONIO – Temporarily suppressing ovarian function with a gonadotropin-releasing hormone analog during chemotherapy helps preserve fertility an...
Video
- Author:
- Susan London
Publish date: December 7, 2017
SAN ANTONIO – The ORR was 15.2% in the phase 1b/2 PANACEA trial of pembrolizumab and trastuzumab in trastuzumab-resistant HER2+ advanced breast can...
Video
- Author:
- Susan London
Publish date: December 7, 2017
SAN ANTONIO – Increasing the dose intensity of adjuvant chemotherapy reduced risks of breast cancer recurrence and death by about 15% in an EBCTCG ...
News
- Author:
- Susan London
Publish date: December 1, 2017
The results support recommendations made by the Infectious Diseases Society of America and the National Comprehensive Cancer Network.
